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Summary 
Whereas there is ample evidence for involvement of the p55 tumor necrosis factor (TNF) receptor 
(p55-R) in the cytocidal effect of TNF, the role of the p75 TNF receptor (p75-R) in this effect 
is a matter of debate. In this study, we probed the function of p75-R in cells sensitive to the 
cytotoxicity of TNF using a wide panel of antibodies (Abs) against the receptor's extracellular 
domain. Two distinct Ab effects were observed. The Abs triggered signaling for cytotoxicity. 
This effect: (a) was correlated with the extent ofp75-R expression by the cells; (b) was dependent 
on receptor cross-linking by the Abs; (c) occurred in HeLa cells, but not in A9 cells transfected 
with human p75-R or in HeLa cells expressing cytoplasmically truncated p75-K mutants, indicating 
that it involves cell-specific activities of the intraceUular domain of the receptor; (d) was synergistic 
with the cytoddal effect of Abs against p55-K. Moreover, it seemed to reverse induced desensitization 
to the cytocidal effect of anti p55-R Abs, suggesting that it involves mechanisms different from 
those of the signaling by the p55 TNF-K.  In addition, the Abs affected the response to TNF 
in a way that does not involve the signaling activity ofp75-R. These effects: (a) could be observed 
also in cells in which only p55-R signaled for the cytocidal effect;  (b) were not dependent on 
receptor cross-linking by the Abs;  (c) varied according to the site at which the Abs bound to 
the receptor; and (d) were correlated inversely with the effects of the Abs on TNF binding to 
p75-K. That is, Abs binding to the membrane-distal part of the receptor's extracellular domain 
displaced TNF from the p75 receptor and enhanced cytocidal effect, whereas Abs that bind to 
the membrane-proximal part of the extracellular domain -  a region at which a conformational 
change seems to take place upon TNF binding -  decreased the dissociation of TNF from p75-K 
and inhibited its cytoddal effect. The above findings suggest that p75-R contributes to the cytocidal 
effect of TNF both by its own signaling and by regulating the access of TNF to p55-R. 
T 
NF initiates its multiple effects on cell function by binding 
to two distinct cell surface receptors (1-8).  These two 
receptor species (p55-R I and p75-Rs) are expressed in many 
cell types, in various amounts and proportions. Both also exist 
in soluble forms, which are derived proteolytically from the 
extracellular domain of the corresponding cell surface form 
1 Abbreviations used in thispa~r: A9p75WT, A9 cells expressing  transfected 
wild type p75 TNF receptor; A9 p75CT, A9 cells expressing  transfected 
cytoplasmically  truncated p75 TNF receptor; ABTS, 2, 2'-azino-bis-(3- 
ethylbenzthiazoline-6-sulfonic  acid)i CHI, cycloheximide;  HeLa  p75WT, 
HeLa cells  expt~sing  transfected  wild-type  p75 TNF receptor;  HeI.a  p75CT, 
HeLa cells expressing transfected cytoplasmically  truncated p75 TNF 
receptor; IP'IG, isopropyloB-D-thiogalactopyranoside;  MBP, maltose  binding 
protein; NGF, nerve  growth factor; p55-R, p55 TNF receptor; p75-R, 
p75 TNF receptor; RIPA, Tris-HCl, NaC1, NP-40, deoxycholate,  SDS, 
EDTA; TNF-R, TNF receptor. 
(2, 9-11).  The soluble TNF receptors (TNF-R) bind TNF 
in a reversible  manner and can thus affect its access to the 
cell-surface receptors as well as its stability (12). 
There is significant sequence homology between the ex- 
traceUular domains of the two receptors. Both contain a four- 
fold repetition of a sequence module characterized by con- 
served location of several (usually six)  cysteine residues,  as 
well as of some other amino acid residues (4-8). Homolo- 
gous repetitive cysteine-rich modules occur in the extracel- 
lular domains of a number of other receptors (the TNF/nerve 
growth factor [NGF] receptor family), including the low- 
affinity NGF receptor (13),  the B cell antigen CD40 (14), 
the lymphoid activation antigen OX40 (15), the T cell an- 
tigens 4-1BB  (16) and CD27 (17), the CD30 antigen (18), 
the Fas/APO-1 receptor (19, 20), and the T2 pox virus gene 
product  (21).  Significant structural  homology among the 
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evolved from a common ancestral receptor-ligand pair and 
that the conserved structural features of the repetitive cysteine- 
rich module underlie conserved common features of their ac- 
tion mechanisms (22-27). 
Knowledge of the structural basis of TNF-R function is 
primarily confined to the p55-R species.  X-ray analysis of 
co-crystals of its soluble form with TNF-B has provided in- 
formation on the way in which p55-R  binds  TNF  (28). 
Detailed mutational studies of its intracellular and "spacer" 
regions (the region that links its cysteine-rich module to the 
transmembrane domain) have revealed motifs that are involved 
in its  signaling  and in  its  induced shedding  (29-32,  and 
Brakebusch C., E. Varfolomeev, M. Batkin, and D. Wallach, 
manuscript in preparation).  Many of the known effects of 
TNF can be induced in cells by the use of Abs against the 
extracellular domain of p55-R, indicating that the signaling 
activity of this receptor species suffices for their induction 
(e.g. 33, 34). The efficacy of induction is correlated with the 
extent of receptor cross-linking by the Abs, suggesting that 
initiation of the signaling activity of p55-R involves receptor 
aggregation (33). 
The nature of the signaling mechanisms of p55-R  and 
p75-R is not known. However, the lack of structural similarity 
between their intraceUular domains suggests that they pro- 
vide distinct signals. Indeed, several studies indicate that the 
two TNF-tLs  can induce different effects (35-38).  Other 
studies suggest, however, that at least some of the effects of 
TNF induced by p55-R, for example its cytocidal effect, are 
also affected by p75-R activity or activities (39-45). In some 
of these studies it was suggested that p75-R assists the in- 
duction of such TNF  effects by enhancing the binding of 
TNF to p55-R (38),  and in others that p75-R contributes 
via its own signaling activity (42,  44). 
In this study, we explored the functional interactions of 
the two TNF-tLs by analyzing the effects  of Abs against 
different regions in the extracellular domain of p75-R on TNF 
cytotoxicity. Our analysis confirmed that p75-R can partici- 
pate in the cytocidal effect and indicated that its contribution 
includes two distinct kinds of activities.  One of them, sig- 
naling for the cytocidal effect, known to be triggered by p55-R, 
was conclusively shown here to be triggered by p75-R as well. 
This signaling activity seems to emanate from the intracel- 
lular domain of p75-R and, like the signaling activity of p55- 
tL, can be triggered by Ab-mediated receptor cross-linking. 
Second, by controlling the access of TNF to p55-1L, p75-R 
appears  to regulate p55-R-mediated cytotoxicity. This ap- 
parent activity of p75-R is also affected by Abs but is inde- 
pendent of receptor cross-linking. It appears to involve the 
extracellular domain of p75-R,  not only in its membrane- 
distal part, to which TNF binds, but also in its membrane- 
proximal part, where a conformational change seems to take 
place upon TNF binding. 
Materials  and Methods 
Abs and Their Characterization 
A panel of 23 mAbs against human p75 TNF-R. was established 
by immunizing mice with the soluble  urinary receptor, as described 
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for the development of Abs against p55-R (33). Cross-competition 
analysis of the binding of these Abs to the soluble receptor (33) 
showed that they bind to five epitopes, denoted here as epitope 
A (14 Abs), B (Abs number 31 and 41), C (36 and 62), D (67 and 
81), and E (32, 57, and 70). 
Monovalent Fab fragments of the mAbs were produced either 
by cleavage  with papain, as described  previously  (33), or with pepsin, 
followed by reduction,  alkylation, and purification on a protein 
G-Sepharose column (Pharmacia, Uppsala, Sweden) (46). 
Rabbit polydonal Abs against the spacer region in p75-K, which 
extends between  the transmembrane domain and the COOH- 
terminal cysteine in the extracellular domain, were raised against 
a recombinant protein consisting of amino acids 181-235 of p75-R 
(numbered according to reference  47), fused to the maltose-binding 
protein (MBP). This fusion protein, produced using the pMal-cRI 
vector (New England Biolabs Inc., Beverly, MA), was expressed 
in protease-deficient BL21 bacteria and purified on an amylose 
column according to the manufacturer's instructions. The Abs were 
purified by ammonium sulfate precipitation and Abs against MBP 
were then removed by their adsorption on an irrelevant MBP fu- 
sion protein. Flow cytometry demonstrated their binding to the 
native receptor expressed by HeLa cells. Concentrations of these 
Abs are specified  in terms of dilution, compared to their initial con- 
centration in the serum. 
Mouse monodonal and rabbit polyclonal  Abs against the soluble 
form of human p55-R were produced as described (2, 33). Rabbit 
polyclonal Abs against mouse p55-R were raised by immunizing 
rabbits with recombinant extracellular domain of mouse p55-R 
fused to MBP, produced using the pMal-p vector. The monoclonal 
anti-IL-6 Ab (number 34.1), used here as an isotype-matched nega- 
tive control for the flow cytometry experiments, was a gift from 
Interlab Laboratories (Ness-Ziona, Israd). FITC-labeled goat Ab 
against the Fab fragment of mouse IgG was obtained from Biomakor 
(Rehovot, Israel). Goat Ab against mouse IgG was obtained from 
Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA). 
Affinity-purified goat anti-rabbit  Ig, goat anti-rabbit  Igs linked 
to horseradish peroxidase, and goat anti-mouse Igs linked to horse- 
radish peroxidase were obtained from Biomakor. 
Establishment of  HeLa and A9 Cell Transfectants  that Overexpress 
the Wild-type or Cytoplasmically Truncated  p 7  5-R 
Human HeLa (48) and mouse A9 (49) cells were grown in 
DMEM supplemented with 10% FCS, 100 U/ml penicillin, and 
100 #g/ml streptomycin. The cDNA for human p75-1L was ob- 
tained by screening a kgtll cDNA library of U937 cells (Clon- 
tech, Palo Alto, CA) with oligonucleotides corresponding to the 
published sequence of the receptor (7). The 5' and 3' untranslated 
regions were deleted (upstream from nucleotide 90 and downstream 
from nucleotide 1476, according to the numbering of reference 7), 
and the receptor was expressed  in the pMPSVEH expression  vector, 
under control of the myeloproliferative  sarcoma  virus promoter (50), 
either fully or after cytoplasmic deletion, downstream from Gin 
264 or from Gin 273. The receptor constructs, together with the 
pSV2neo plasmid conferring resistance to neomycin, were trans- 
fected to the A9 and HeLa cells by the calcium phosphate precipi- 
tation method. Expression  of the transfected  receptor in clones resis- 
tant to G418 (500 #g/ml; Sigma Chemical Co., St. Louis, MO) 
was assessed  by determining both the binding of radiolabeled TNF 
and that of monoclonal anti p75-tL Abs to the cells, levels ofp75-R 
were quantified by measuring the binding of radiolabeled TNF at 
saturating concentrations  to the ceils  in the presence  of an Ab against 
p55-tL (number 18). In all experiments, testing of cells of several 
clones overexpressing p75-R yielded qualitatively similar results. 
Role of p75 TNF Receptor in TNF Cytotoxicity The presented data concerning the Hela cells that overexpress  wild- 
type p75-K (HeLa p75 WT) refer to a specific  clone that expressed 
about 72,000 TNF-R per cell. The effect of cytoplasmic trunca- 
tion on p75-R function was tested in A9 cells by expressing the 
receptor truncated downstream from Gln 264. In HeLa cells, ex- 
amination of mutants  truncated downstream from Gln 264 and 
from Gin 273 revealed the same phenotype in both. 
Assay of Cytocidal Activity of TNF and A bs against the Receptors 
Recombinant  human TNF-ce (6  x  10  7 U/mg protein)  was 
used,  except in  the indicated cases, where recombinant  mouse 
TNF-c~ (4  x  10  7 U/rag protein) was employed. Both were pro- 
duced by Genentech, Inc. (South San Francisco, CA) and kindly 
provided by Dr. G. Adolf (Boehringer Institute, Vienna, Austria). 
Unless otherwise stated, the cytocidal effects of TNF and of anti 
TNF-R Abs in the HeLa cells were assessed by applying TNF or 
the Abs to the cells for 10 h, in the presence ofcycloheximide (CHI, 
25 gg/ml). The A9 cells were treated with TNF or the Abs for 
12 h, in the presence of 50 #g/ml CHI. Cell viability was deter- 
mined by the neutral-red uptake method, as described elsewhere 
(51). The cytocidal effects of Abs against p75-R and of their Fab 
fragments after cross-linking with anti-Ig Abs, were assessed as 
described for Abs against p55-R (33). All tests were performed 
in triplicate. Viability of treated cells is presented as a percentage 
of the viable cells in cultures incubated with CHI alone  _+  stan- 
dard deviation. Results of the cytotoxicity tests are representative 
of sets of  at least three independent experiments that yielded similar 
results. 
Quantification of TNF Binding to Cells and of its 
Modulation by Anti-p75 Abs 
TNF was labeled with ~2sI by the chloramine-T method, as pre- 
viously described (52), to a specific  radioactivity of 1,500 Ci/mmol. 
Specific binding of the radiolabeled TNF applied to the cells for 
2 h at 4~  at a concentration of  0.5 nM, in the presence or absence 
of Abs against TNF-R, was determined as described (53). 
The effects of anti p75-R Abs and of their Fab monovalent frag- 
ments on the rate of TNF dissociation from the receptors were 
assessed as follows: radiolabeled TNF was applied to the cells in 
PBS containing  154 mM NaC1, 10 mM sodium phosphate, pH 
7.4, at a concentration of 1 nM, in the presence or absence of 10 
gg/ml of the Abs. After incubation for 8 h, the cells were rinsed 
twice with ice-cold PBS to remove unbound TNF, and incubated 
further with PBS containing the Ab (10 #g/ml), 0.5% liSA, 0.02% 
sodium azide, and unlabeled TNF (0.1 gM), for the indicated time 
periods. They were then rinsed once with cold PBS, and the cell- 
bound radioactivity was determined.  The data presented are av- 
erage values for quadruplicate samples. 
Quantification of Ab Binding to p75-R  and of Its 
Modulation by Pretreatment with TNF 
The extent and efficacy  of binding of the various Abs to p75-K 
were assessed by the following three procedures: 
Flow Cytometry.  After treatment with TNF, nearly confluent 
HeLa p75WT cells were detached in PBS containing 5 mM EDTA 
and then incubated sequentially with anti p75-R Abs at various 
concentrations, and with FITC-labeled goat Ab against the Fab 
fragment of mouse IgG at a dilution of 1:20. Each incubation was 
carried out for 30 rain at 4~  The fluorescence intensity of the 
cells was analyzed using a FACScan  |  flow cytometer (Becton Dick- 
inson & Co., Mountain  View, CA). 
Immunoprecipitation of the Receptor  Nearly confluent  HeLa 
p75WT cells were treated with TNF and then rinsed with cold 
PBS containing 0.5% BSA. They were then incubated for 1.5 h 
on ice in the same buffer containing the indicated monoclonal anti 
p75-R Abs at a concentration of 10 #g/ml, or polydonal Abs against 
p75-R spacer region at a dilution  of 1:100. The cells were then 
washed, lysed, and extracted with RIPA buffer (10 mM Tris-HCl, 
pH 7.5, 150 mM NaC1, 1% NP-40, 1% deoxycholate, 0.1% SDS, 
and 1 mM EDTA), supplemented with I mM PMSF and 10 mM 
benzamidine HC1. Insoluble material was pelleted by centrifuga- 
tion for 30 min at 30,000g. Ab-receptor complexes were adsorbed 
on protein G--Sepharose  beads for 4 h at 4~  The beads were washed 
thoroughly with RIPA buffer and PBS, resuspended, and boiled 
in SDS sample buffer containing mercaptoethanol. After SDS-PAGE 
(10% acrylamide), the proteins were Western blotted on nitrocel- 
lulose sheets (Schleicher & Schuell, Dassel, Germany) and probed 
with rabbit polyclonal Abs against the soluble form of p75-R,  or 
(when immunoprecipitation  was performed with antispacer Abs) 
with mAb number 32. The amount of Ab bound to the blots was 
determined by incubating the blots with goat anti-rabbit  or goat 
anti-mouse  Ab conjugated to horseradish peroxidase, and meas- 
uring the amount of bound conjugated lib after further incuba- 
tion with diaminobenzidine (Sigma Chemical Co.) and hydrogen 
peroxide. 
CelI-ELISA of Abs Bound to the Cell in the Presence of Deter- 
gent.  Confluent monolayers  ofHeLa  p75WT cells in 96-microwell 
plates were treated with TNF, thoroughly rinsed with ice-cold  PBS 
containing 1 mM calcium chloride and 1 mM magnesium chlo- 
ride, and fixed with glutaraldehyde (0.1% in PBS) for 40 rain at 
4~  Free aldehyde  groups were blocked by incubation of the cells, 
first for 30 rain at 37~  with 100 mM glycine in PBS, and then 
for 2 h  with  PBS, 0.5% BSA, 0.05%  Tween-20, and  0.05% 
NAN3. The plates were rinsed with PBS containing 0.05% Tween- 
20 and incubated in the same buffer for 2 h at 4~  with the indi- 
cated concentrations of the Abs. The cells were rinsed with RIPA 
buffer, and the amounts of  Ab bound to the cells were determined 
by incubating the cells with goat anti-mouse or goat anti-rabbit 
Ab conjugated to horseradish peroxidase followed by further incu- 
bation with 2, 2'-azino-bis-(3-ethylbenzthiazoline-6-sulfonic acid) 
(A8~; Sigma Chemical Co.) and hydrogen peroxide. Alternatively, 
Ab binding was quantified using preparations of Abs radiolabeled 
by the chloramine-T method (52). After binding of these Abs to 
the glutaraldebyde-fixed  cell monolayers, the wells were rinsed with 
ILIPA buffer, and Abs bound to the cells were detached in 2% SDS 
solution and quantified using a "f-counter. 
Mapping ofEpitope E.  DNA sequences  encoding different over- 
lapping parts of the extracellular domain of p75-R were produced 
by PCR; using the full-length cDNA as template. The antisense 
primers used for the PCR reaction contained a stop codon. The 
DNA sequences were introduced into the pET8c vector (54) or 
were expressed in  fusion  with  MBP  by introduction into  the 
pMalcRI vector (New England Biolabs, Inc.). Bacteria (BL21) ex- 
pressing these proteins upon induction  with isopropyl-~8-D-thio- 
galactopyranoside (ItrlG; Pharmacia) were resuspended in  SDS 
sample buffer containing ~-ME, denatured by boiling, and sub- 
jected to SDS-PAGE (10 or 12% acrylamide) followed by Western 
blotting.  The blots were incubated sequentially with a blocking 
solution containing 154 mM NaC1, 10 mM sodium phosphate, pH 
7.4,  0.05%  Tween-20, 10%  (vol/vol) bovine milk  and 0.25% 
(vol/vol) normal goat serum, with an Ab against epitope E and 
with radiolabeled goat Ab to mouse IgG, and were then autoradi- 
ographed. Alternatively, binding of Abs to the blots was probed 
using goat anti-mouse Ab linked to horseradish peroxidase, as de- 
scribed above. The identity of the recombinant fragments of the 
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of the IPTG-induced protein in the bacterial extracts by SDS-PAGE, 
and by interaction of the Western blot with polyclonal antiserum 
against soluble p75-R. 
Involvement of the cysteine residues within epitope E in its rec- 
ognition by Abs was explored in two ways: first, by determining 
whether the Abs interact with a recombinant protein corresponding 
to amino acids 3-181 of p75-1L, where cysteine 179 was replaced 
by alanine,  This protein (3-181 C -~ A) was produced and exam- 
ined as described above, except that the antisense primer for PCR 
amplification contained the mutation (5' CTC GGA TCC TCA 
CGT GGA CGT [GGC] GAC TGC ATC CAT 3'). Second,  the 
effect of alkylation of cysteine residues was assessed before and after 
reduction. A recombinant fusion protein, consisting of MBP fused 
to amino acids 125-192  of p75-R, was purified by adsorption on 
an amylose column and alkylated with iodoacetamide (75 mM for 
1 h) before or after treatment with 100 mM dithiothreitol.  It was 
then subjected to Western blotting as described above. 
The mapping of the epitope was further confirmed by assessing 
the interaction of Abs against epitope E with synthetic peptides 
produced by t-Boc chemistry on a peptide synthesizer (model 430 
A; Applied Biosystems, Foster City, CA). ELISA plates were coated 
with  a fusion protein consisting  of MBP fused to  amino acids 
125-192  in p75-tL,  produced as described above,  and purified by 
adsorption on amylose. The protein, at a concentration of 1/~g/ml 
in PBS/0.02%  sodium azide, was applied to the plates for 2 h. 
After further incubation of the plates for 2 h with a solution con- 
taining PBS, 0.5% BSA, and 0.02% sodium azide (blocking solu- 
tion),  an Ab against epitope E was applied for 2 h  to the plates 
at a concentration of 1/~g/ml, with or without one of the syn- 
thetic peptides. The amounts of Ab bound to the protein-coated 
plate were determined by the use of goat anti-mouse Ig Ab con- 
jugated to horseradish peroxidase and ABTS,  as described above. 
Results 
Abs against p75-TNF-R Can Trigger Signaling for a Cyto- 
cidalEffect.  HeLa cells predominantly express p55-R and are 
killed by agonistic Abs against this receptor species, but not 
by Abs against p75-R (Fig.  1 A). To examine the involve- 
ment of p75-R in the cytocidal function of TNF, we trans- 
fected HeLa cells with p75-R cDNA and isolated clones of 
cells expressing large amounts of the receptor (HeLa p75WT, 
Fig. 1 C). In these cells, Abs against p75-R triggered a mild 
cytocidal effect. Moreover, they potentiated the cytocidal ac- 
tivity of simultaneously applied Abs against p55-R (Fig.  1 
B). The intensity of these effects varied among different trans- 
fected clones, roughly in proportion to their p75-R levels. 
To investigate the mechanism whereby anti p75-R Abs exert 
their own cytocidal effect, we compared the ability of var- 
ious individual Abs, or Ab combinations, to trigger such an 
effect. We employed 23 different mAbs raised against the 
soluble form of p75-R and antiserum raised against the spacer 
region in the receptor (a region not included in the soluble 
form of the receptor,  extending between the cysteine-rich 
module in the extracellular domain and the transmembrane 
domain). Cross-competition analysis of their binding to soluble 
p75-R showed that the mAbs bind to five epitopes, denoted 
A to E. Table 1 presents a summary of the observed effects 
of the different Abs on HeLa p75WT cells, as well as on 
the other cells used in this study. 
As shown in Fig. 2 A, Abs against p75-R were most effec- 
tive when applied in combinations that bind to different epi- 
topes, This increased efticacy was observed both when the 
anti p75-R Ab combinations were applied alone to HeLa 
p75WT cells and when applied in the presence of Abs against 
p55-R.  Indeed, when applied alone,  the anti p75-R Abs 
showed significant cytocidal activity only in such combina- 
tions. Abs against  p55-R greatly potentiated the cytocidal 
effect of the anti p75-R Abs and in their presence the in- 
dividual Abs and the combinations of Abs that bind to the 
same epitope also had some effect. The magnitude of the effect 
varied, depending on the epitope to which the Abs bound; 
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Figure  1.  Additive  cytocidal effects of p75-R 
and p55-R in HeLa cells transfected with p75-IL 
Comparison of the cytocidal  effects  of anti TNF-R 
Abs in (A) normal HeLa cells (expressing about 
500 p75-Rs per cell) and (/3) a clone of HeLa calls 
transfected with an expression vector containing 
p75-IL cDNA (HeLa p75WT cells) and therefore 
expressing increased amounts of the receptor  (about 
72,000 p75-Rs per cell). The cytocidal effects of 
Abs against p55-R (O, mixture of Abs 18 and 20, 
which recognize distinct epitopes [33]), of Abs 
against p75-R (A, mixture of Abs 13, 36, and 41, 
which recognize distinct epitopes), and of their 
combination (I), applied at the indicated concen- 
trations, were assessed  as described in Materials and 
Methods. (C) Flow cytometric analysis of expres- 
sion of p55 (left)  and p75 (right)  TNF-R in the 
normal and transfected HeLa cells examined in A 
and B. Cells were incubated consecutively with 
mAbs  against p55-R  (number  20)  or  p75-R 
(number 14), or with isotype-matched  control anti- 
IL-6 Abs (background),  all at a concentration of 20 
/~g/ml,  and  then  with  FITC-conjugated  goat 
anti-mouse Ig Ab (see Materials and Methods for 
details). 
448  Role of p75 TNF Receptor in TNF Cytotoxicity Table  1.  Effects of Abs Against p75-R on HeLa and A9 Cell Expressing Wild-type and 
Cytoplasmically Truncated p75-R 
EPITOPE: 
(~y~;TEINE-RICH MODULE 
Intact  lab  Intact  Fab  Intact  Fab 
SPACER 
REGION 
Intact  lab 
Ab  EFFECTS  INDICATING 
SIGNALING  BY THE  075-R 
ON ~YTOTOXICITY  OF ANTI O55-R Abs 
IN HELA CELLS EXPRESSING WT p75-R  4-  4-  ,-  ,- 
IN HELA CELLS EXPRESSING CT p75-R 
& IN A9 CELLS 
INFERRED  MODE  EFFECTIVE  EFFECTIVE  WEAK  WEAK 
OF Ab  ACTION  TRIGGERING  TRIGGERING  TRIGGERING  TRIGGERING 
Ab  EFFECTS  INDICATING 
CONTROL  BY THE nTS-R 
OF TNF  AVAILABILITY 
TO THE DS5-R 
ON CYTOTOXICIXY  OF TNF  I 
IN.E  CELLSEXPRESS,NG  W.7 -R  4  --  4, 
& IN A9 CELLS 
At) EFFECT  ON TNF BINDING 
TNF EFFECT  ON Ab BINDING  ##  ##  ## 
INFERRED  MODE  INCREASED  DECREASED  DECREASED  DECREASED 
OF Ab  ACTION  AVAILABILITY  AVAILABILITY  AVAILABILITY  AVAILABILITY 
OF TNF  OF TNF  OF TNF  OF TNF 
4~, stimulation; ~1,, weak stimulation; ~,  Inhibition;  --,  No effect; ND, Not determined. 
it was lowest, indeed barely detectable, with the Abs against 
epitope E and against the spacer region (Fig. 2, A  and C). 
Combinations of Abs that bind to different epitopes can 
cause extensive aggregation of the antigen molecules to which 
they bind,  whereas Abs that bind to a single epitope  are 
capable, at most, of linking the antigen molecules in couples. 
The greater cytocidal activity of combinations of Abs that 
bind to different epitopes in p75-R suggests that the receptors 
are triggered as a consequence of their cross-linking.  This 
notion gained further support when we examined the cyto- 
cidal activity of Fab monovalent fragments of an Ab against 
epitope A. In contrast to the intact Ab, its Fab fragments 
were without cytocidal effect, even when applied in the pres- 
ence of Abs against p55-R (Fig. 2 B). These Fab fragments 
did however have a cytocidal effect when cross-linked with 
anti-Ig Abs. Moreover, antiolg Abs enhanced the cytocidal 
activity of the intact Ab molecules (Fig. 2 B). Also, cross- 
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linking of the Abs against epitope E or the spacer region, 
which by themselves had almost no cytocidal effects, resulted 
in some cytotoxicity (Fig. 2 C). 
Signaling by p75-R  Appears to Interact with Signaling by 
p55-R.  The more than additive effect of Abs against the 
two TNF-Rs suggests that, even though they initiate  the 
same effect, they do so by different signaling mechanisms. 
To explore further the relationship between the mechanisms 
of cytotoxicity  induction by the two receptors, we examined 
whether triggering of one of them can cross-desensitize the 
cells to the effect of the other.  The cytocidal effect of Abs 
against p55-R was previously shown to be subject to homol- 
ogous desensitization (33). As shown in Fig. 3, HeLa p75WT 
calls pretreated with anti p55-R Abs in the absence of a pro- 
tein synthesis blocker (which in these cells is needed to didt 
TNF cytotoxicity) showed almost no cytoddal effect  following 
a second exposure to these Abs in the presence of a protein 11111 
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Figure 2.  Cytocidal effects of Abs against p75-R in HeLa cells expressing wild-type p75-R reflect cross-linking of the receptors.  (A) Cytocidal 
effects of individual Abs, combinations of Abs that bind to the same epitope, and combinations of Abs that bind to different epitopes in the absence 
(left) and presence (right) of Abs against p55-K. The cytocidal effects of the various anti-p75-R mAbs were assessed in HeLa p75WT cells, in the 
absence or presence of Abs against p55-R (numbers 18 and 20, both applied at a concentration of I #g/ml). Anti p75-K Abs were applied, each at 
a concentration of 2/~g/ml, individually (Single Ab: epitope A, number 14; epitope B, 41; epitope C, 36; epitope D, 67; epitope E, 32), in combinations 
of several Abs that bind to the same epitope (Several against the same epitope: epitope A, 14, 20,  and 22;  epitope B, 41, 47, and 82;  epitope C, 36 
and 62; epitope D, 67 and 81; and epitope E, 32, 57, and 70) or in combinations of Abs that bind to different epitopes (Several against di~erent epitopes: 
A+B+C,  14, 41, and 36; A+B+D,  14, 41, and 67: A+C+D,  14, 36,  and 67; C+D,  36 and 67; C+D+E,  36,  67,  and 32).  (B) Cytocidal effects 
on HeLa p75WT cells of an Ab against epitope A in p75-R (E3, number 19) and of its Fab monovalent fragments (O), and their effects on these 
cells after their further cross-linking by goat anti-mouse Fab Abs (GaM, e,  m; see Materials and Methods). The cytocidal effects were assessed in 
the presence of Abs against p55-R (rabbit polyclonal serum against the soluble form of the receptor (2), applied at a dilution of 1:500). (C) Cytocidal 
effects on HeLa p75WT cells of an Ab against epitope E in p75-R (A, number 32) and of antiserum against the spacer region in this receptor ((~), 
and effects on these cells after further cross-linking of the Abs with anti-Ig Abs (A,  ~,,  goat anti-mouse Fab and goat anti-rabbit Ig Abs [GaM 
and GaR], respectively). The cytocidal effect of the mAb against epitope E was assessed in the presence of rabbit polyclonal Abs against p55-R (applied 
at a dilution of 1:250). The effect of the antiserum against the spacer region was determined in the presence of mouse mAbs against p55-R (numbers 
18 and 20, both applied at concentration of I #g/m1). Dotted boxes in B and C indicate the range of the response observed when only the Abs against 
p55-K were applied. 
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Figure 3.  Absence  of  cross-desensitization  by the two TNF-Rs to each 
other's cytocidal  effects.  HeLa p75WT cells were  prdncubated  for 2 h, 
in the absence  of  CHI, with  Abs against  p55-R (numbers  18 and 20, each 
at a concentration  of 1/~g/ml, closed  symbols) or without anti-p55-R Abs 
(open symbols). The cytocidal  effects  of anti-p55-R Abs ([-1, II, numbers 
18 and 20), of anti p75-R Abs (O, I), numbers 13, 36, and 41), and of 
their combination  (O, '), at the indicated  concentrations,  were  subse- 
quently  assessed  in the presence  of  25/~g/ml  CHI, as described  in Materials 
and Methods. 
synthesis blocker. They were not, however, desensitized to 
the effect of anti p75-R Abs. On the contrary, p75 treatment 
of cells desensitized to the effect of anti p55-R Abs resulted 
in a more than additive cytocidal effect, much greater than 
that induced in HeLa p75WT cells by Abs against either of 
the receptors alone (Fig. 3 A). A  similar synergy was ob- 
served when cells pretreated with anti p75-R Abs were chal- 
lenged with Abs against p55-K (data not shown). No desen- 
sitization was observed when cells pretreated with anti-p55-R 
Abs were challenged by Abs against both receptors (Fig. 3 B). 
Effects of Anti-p75-R  Abs on the Cytotoxicity of TNF Point 
to an Additional Mode of Receptor Function.  Application  of 
anti-p75-R Abs to HeLa p75WT cells in the presence  of  subop- 
timal TNF concentrations  resulted, with most of the Abs, 
in enhancement of TNF cytotoxicity. This enhancement is 
consistent  with the observed ability of the Abs to trigger 
a cytocidal effect when applied alone. As in that case, the 
enhancement appeared to be a consequence of receptor cross- 
linking by the Abs: it was most pronounced when the Abs 
were applied in combinations  that bind to different epitopes 
(Fig. 4 A). Moreover, enhancement of TNF cytotoxicity  was 
not observed with Fab monovalent fragments of the Abs, 
but appeared when these fragments were cross-linked with 
anti-Ig (Fig. 4 B). 
Unlike most of the other Abs, however, the three that bind 
to epitope E did not enhance the cytotoxic activity of TNF, 
but rather inhibited it (Fig. 4, A and C). Also, the Abs raised 
against the spacer region had a slight though significant in- 
hibitory effect on TNF function (Fig. 4 C). These inhibitory 
effects, unlike the enhancement of TNF cytotoxicity by the 
other Abs, were also observed when monovalent  Fab frag- 
ments of the Abs were applied. This suggests the involve- 
ment of mechanism(s) independent of receptor cross-linking 
(Fig. 4 C).  Some inhibition of the cytocidal effect of TNF 
was also observed in the presence of Fab monovalent  frag- 
ments of the Abs against epitope D (Fig. 4 C), even though 
in the intact form these Abs enhanced TNF cytotoxicity  (Fig. 
4, A  and C). 
Whereas they inhibited the cytocidal  effect  induced by TNF, 
Abs against epitope E and against the spacer region did not 
interfere with the induction of a cytocidal  effect  by Abs against 
p55-R (Fig. 2 C), nor did they interfere with enhancement 
of the cytocidal effects of anti p55-R Abs or of TNF by other 
anti p75-R Abs. (Compare the effect of the combination of 
Abs that bind to epitopes C, D, and E with that of the com- 
bination of  Abs against C and D only, in Figs. 2 A and 4 A.) 
An Additional Mode Of  p75-R Function Is also Apparent in 
HeLa Cells Transfected witk Cytoplasmically Truncated  p75-R 
Mutants.  To examine the involvement  of the intracellular 
domain in the activities ofp75-R, we transfected HeLa cells 
with cDNAs encoding cytoplasmically truncated mutants of 
the receptor (HeLa p75CT). In contrast to cells expressing 
large amounts of the wild-type p75-R (HeLa p75WT), which 
responded normally to the cytocidal effects  of anti-p55-R Abs 
and of TNF, all clones expressing p75-R mutants (truncated 
below Gin 264 or Gin 273) were relatively resistant to such 
cytotoxicity. Anti-p75-R Abs had no effect at all when ap- 
plied alone to cells expressing the receptor mutants, nor did 
they enhance the mild cytotoxicity of Abs against p55-R. 
Thus, as with p55-R (29-31), triggering of cytotoxicity by 
p75-R seems to depend on the integrity of the receptor's in- 
tracellular domain. A representative example of the data is 
presented in the legend to Fig. 4 D. 
Although unable to initiate signaling for the cytocidal effect 
in HeLa p75CT cells, anti-p75-R Abs did affect the extent 
of cell killing by simultaneously applied TNF. Abs against 
epitope E or their Fab monovalent fragments inhibited the 
cytocidal effect of TNF, whereas Abs against epitope A en- 
hanced it to a small but significant extent (Fig. 4 D). In con- 
trast to the case where the Abs were applied together with 
TNF to HeLa p75WT cells, this latter enhancement could 
also be observed with Fab monovalent fragments of the Abs 
(Fig. 4 D); it therefore seems to involve not triggering of 
the signaling activity ofp75-R, but some other mechanism(s), 
possibly related to the ability of the anti-A Abs to displace 
TNF from p75-R (see below). 
Effects of Anti-p75-R  Abs in A9 Ce!ls Transfected with tke 
Human Receptor Support a 'Nonsignaling' Role of  p75-R in TNF 
Function.  To determine whether the effects of anti-p75-R 
451  Bigda et al. Figure  4.  Enhancement and in- 
hibition of the cytocidal effect of 
TNF by anti-p75-R Abs in HeLa 
cells expressing wild-type  p75-R or 
a cytophsmically  truncated p75-R. 
(.4) Effects on TNF cytotoxicity  of 
individual Abs, combinations of Abs 
that bind to the same epitope, and 
combinations of Abs that bind to 
different  epitopes.  The  cytocidal 
effects of the various  monoclonal 
anti-p75-R Abs on HeLa p75WT 
cells were assessed in the presence 
of TNF (50 U/m1).  The Abs and 
their concentrations are as in Fig. 
2 A. (B) Effects of an Ab against 
epitope A (e, ,,  number 19) and 
of  its Fab monovahnt fragments (O, 
[]),  with or without  their cross- 
linking by goat anti-mouse Fab Abs 
(CAM), on the cytoddal effect of 
TNF (20 U/ml) in HeLa p75WT 
cells. (C) Effects of Abs against epi- 
tope D (V, number 67) and E (', 
number 32), antiserum against the 
spacer region in p75-R (&) and Fab 
monovalent fragments of these Abs 
(~7, O, A) on the cytocidal effect 
of TNF (50 U/mi) in HeLa p75WT 
cells. (/9) Effects of an Ab against 
epitope A (e,  number 13) and of 
its Fab monovalent fragments (O) 
and effects of an Ab against epitope E (,,  number 32) and of its Fab monovalent fragments (~)  on the cytocidal effect of TNF (1,000 U/ml) in 
HeLa cells expressing cytoplasmic.ally truncated p75-R (HeLa p75CT,  about 140,000 receptors per cell). When applied alone to the HeLa p75CT cells, 
anti-p75-R Abs (numbers 14, 62, and 82, each at a concentration of 20/~g/ml) had no effect on TNF cytotoxicity, nor did they enhance the cytotoxicity 
induced by anti-p55-R Abs (numbers 18 and 20, each applied at a concentration of 20/~g/ml, which caused killing of 17  _+  3% of the cells in this 
experiment). Dotted boxes in 8-D indicate the range of the response  observed  when TNF was applied alone to the cells. 
1001 
80 
-~6o  m 
20 
A ~ 
a p75 
al~s 
T'~8 p55+a p75 
0  0.001 0.01  0.1  1  10  100 
I  i  I  I  i 
11320 11160 1180 1140 1/20 
~m 
B  C 
Anti E 
Ant| E Fab 
Anti A 
Anti A Fab 
0  0.01  0.1  1  10  100  0  0.01  0.1  1  10  100 
Antibody Concentration (~glml) 
Figure  5.  Anti-p75-R Abs have 
no cytocidal effect in A9 cells ex- 
pressing  high levels of p75-R but 
do modulate the cytocidal effect of 
TNF on these cells. (.4) Lack of a 
cytocqdal effect of anti-p75-R Abs 
(A, mixture of Abs 13, 36, and 41) 
on  A9  cells  expressing  large 
amounts of full-length p75-K (A9 
p75WT, about 90,000 receptors per 
cell), in contrast to the marked cy- 
totoxicity of an antiserum against 
the routine p55-R (O). Anti-p75-R 
Abs also fail to enhance  the cyto- 
toxicity of the anti routine p55-R 
antiserum (I). (/3 and C) Enhance- 
ment of the cytocidal  effect of TNF 
(1,000 U/m1) by an Ab against epi- 
tope A (O, number 13) and by its 
Fab monovalent fragments (O), and 
Antlaocum  dilution  inhibition of the effect by an Ab 
against epitope E (0,  number 32) and by its Fab monovalent fragments (<)) in A9 cells expressing  wild-type or cytoplasmically  truncated human 
p75-R. (B) A test performed with the same A9 p75WT clone that was tested in A. (C) A test performed with A9 p75CT ("~110,000 receptors per 
cell). Abs against epitope B and, to a lesser extent, Abs against epitope C  also enhanced  the cytocidal effect of TNF in A9 p75WT or A9 p75CT 
cells, whereas  Abs against epitope D  and against the spacer region had inhibitory effects similar to those of the Abs against epitope E. The Abs had 
the same effects when mouse rather than human TNF was used.  Dotted boxes in B and C  indicate the range of the response  observed when TNF 
was applied alone to the cells. 
452  Role of p75  TNF Receptor in TNF Cytotoxicity Abs observed with HeLa cells also pertain to other cells, we 
examined their effect on mouse A9 calls transfected with 
cDNA for the wild-type human p75-R (A9 p75WT) or for 
a cytoplasmically truncated mutant of it (A9 p75CT). AU 
transfected clones exhibited a significantly reduced cytotoxic 
response to TNF, in correlation with the amounts of the ex- 
pressed receptor, but responded normally to the cytocidal  effect 
of Abs against their murine p55-R. Unlike the HeLa p75WT 
calls, A9 p75WT and A9 p75CT cells did not exhibit a cyto- 
cidal effect when treated with Abs against human p75-R, 
nor did these Abs enhance the cytocidal effect induced in the 
cells by Abs against murine p55-R (Fig. 5 A  and data not 
shown). 
Although unable to initiate signaling for a cytocidal effect 
in A9 p75WT or A9 p75CT cells, anti-p75-R Abs strongly 
affected  the killing of these cells by TNF. These effects  resem- 
bled those observed in HeLa p75CT ceils. Abs or Fab monova- 
lent fragments that bind to epitopes D or E, or to the spacer 
region, reduced the cytotoxic response of the ceils to TNF. 
Abs or Fab fragments that bind to epitopes A and B and 
(though to a lesser extent) Abs or Fab fragments that bind 
to epitopes C enhanced the cytocidal effect of TNF in these 
ceils (Fig. 5, B and C  and data not shown). 
Effects of Anti-p75-R Abs on TNF Binding to p75-R.  Abs 
binding to different epitopes in p75-R affected TNF binding 
in quite different ways. The pattern of these effects was al- 
most opposite to that of their effects on TNF function (Fig. 
6). Abs that bind to epitopes A, B, or C, which enhanced 
TNF function in HeLa p75WT calls, were found to inhibit 
TNF binding. This inhibitory effect was greater with the 
Abs that bind to epitopes A or B than to C. However, Abs 
against epitopes D  or E or the spacer region,  all of which 
inhibited TNF function, did not inhibit its binding. In fact, 
ceils exposed to Abs against epitope E exhibited  some in- 
crease in TNF binding (Fig. 6 A). Moreover, measurement 
of the dissociation of TNF from p75-R, which occurs rather 
rapidly (38), revealed that Abs against epitopes D or E and, 
to a lesser extent, Abs against the spacer region inhibit the 
dissociation of TNF from the receptor. Fab monovalent frag- 
ments of the Abs against epitope E had a similar inhibitory 
effect (Fig. 6 B). 
Effects of TNF on Binding of Anti-p75-R  Abs to Epitopes D 
and E and to the Spacer Region.  As shown above, Abs against 
epitopes D or E or the spacer region affected TNF binding 
and function even when in their monovalent form. This sug- 
gests that their effects are rdated to the conformation of the 
receptor molecules rather than to their extent of aggrega- 
tion. The fact that these Abs affect TNF binding and func- 
tion even though the site at which they bind to p75-R seems 
remote from the one at which TNF binding takes place sug- 
gested that the conformation of the receptor at the Ab binding 
site is affected by TNF. To test these notions,  we compared 
the ability of different Abs against the receptor to bind to 
it before and after TNF binding.  Three kinds of tests were 
employed (see Materials and Methods). In the first, the ac- 
tual binding of the Abs to HeLa p75WT cells was quantified 
by flow cytometry. No difference between TNF-treated and 
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Figure  6.  InhibitionorenhancementofTNFbindingtop75-Rbythe 
various anti-p75-R. Abs. (/1) Effects of the various anti-p75-R Abs on TNF 
binding. The effects of Abs against epitope A (I,  number 14), B ([], 
-41), C  (O,  -36) D  (V,  -67) and E (,,  -32) and of Abs against 
the spacer region (A) on the binding of radiohbded TNF to Hel.a p75WT 
cells were assessed as described in Materials and Methods. All Abs binding 
to the same epitope affected TNF binding similarly (data not shown). (/3) 
Kinetics of the dissociation of radiolabeled TNF from HeLa p75WT cells 
in the absence of Abs (O) and in the presence of an Ab against epitope 
D (V, number 67) or E (,,  -70) or its Fab monovalent fragments (~, 
all applied at a concentration of 10/~g/ml) or of Abs against the spacer 
region (&, at a dilution of 1:20). 
untreated cells was observed (data not shown). The other 
two tests probed the efficacy  of Ab binding to p75-R by sub- 
jecting the Ab-receptor complexes to detergent treatment. 
In one, binding ef~cacy  was evaluated  by assessing the recovery 
of the receptor immunoprecipitated from detergent extracts 
of HeLa p75WT cells. In the other, the amounts of Abs bound 
to the receptor were quantified by a ceU-ELISA  procedure. 
In the latter two tests, TNF was found to enhance the 
binding to the receptor of Abs against epitopes E or D  or 
the spacer region, but not that of Abs against the other epi- 
topes. TNF treatment increased the ef~cacy  with which these 
Abs and their Fab monovalent fragments could immunopre- 
cipitate p75-R from detergent extracts of the cells. No such 
453  Bigda et al. Figure 7.  TNF enhances the binding  of Abs to 
epitopes D and E and to the spacer region of p75- 
R: assessment  by immunoprecipitation. Subconflu- 
ent cultures of HeLa p75WT cells were treated 
with TNF (10,000 U/ml) for 10 rain. They were 
then incubated for 90 rain at 4~  with the fob 
lowing Abs: an Ab against epitope A (number 13), 
an Ab against epitope E (number 32) or its Fab 
monovalent fragments,  an Ab against epitope D 
(number  67) or its Fab monovalent fragments, each 
at a concentration  of 10/~g/ml, or Abs against the 
spacer region at a dilution  of 1:100. Unbound  Abs 
were washed offand the cells  were lysed  with RIPA 
buffer, followed by precipitation of  the receptor-Ab 
complexes, SDS-PAGE (10%) and Western blot- 
ting, as described in Materials and Methods. 
effect was observed with Abs against epitopes A, ]3, or C 
(Fig. 7 and data not shown). TNF treatment also significantly 
increased the efficacy with which Abs against epitopes E or 
D  or against the spacer region, but not Abs against A, B, 
or C, bound to (glutaraldehyde-fixed)  cells in a cell-ELISA 
test where cells were rinsed with a detergent solution (Fig. 
8 and data not shown). These effects were specific for TNF. 
They were observed with both TNF-ot and TNF-B (lym- 
photoxin), but not after treatment with IL-lot, which in many 
respects functions similarly to TNF, or with IFN-% shown 
to enhance TNF-R expression  in HeLa cells (52).  In a ki- 
netic study, they could be discerned as early as 1 min after 
TNF was applied to the cells and reached a maximum within 
5 min (data not shown). 
Mapping ofEfito~ E.  The three Abs against epitope E (but 
none of the 20 other mAbs against p75-R) recognized p75-R 
in Western blot analysis, even when the receptor molecules 
were analyzed after their complete denaturation and reduc- 
tion. This enabled us to map epitope E by Western blot anal- 
ysis of the binding of the Abs to various bacterially expressed 
deletion mutants of the extracellular  domain of p75-R (Fig. 
9 B). We found (Fig. 9 A) that NH2-terminal truncation of 
the receptor to Cys 163 and COOH-terminal truncation to 
Thr 179 did not affect recognition by the three Abs. How- 
ever, all further truncations prevented recognition, suggesting 
that epitope E corresponds to the part of the protein that 
extends between the residues Cys 163 and Thr 179. Interac- 
tion of the Abs with a synthetic peptide consisting of amino 
acids 163-179 confirmed this identification (Fig.  9 C). 
As with reduction and denaturation, alkylation with io- 
doacetamide did not affect recognition of the receptor by Abs 
against epitope E in Western blot analysis. However,  recog- 
nition was completely prevented when the receptor was first 
reduced and then immediately alkylated (see Materials  and 
Methods; data not shown). Recognition was also prevented 
by mutational replacement of one of the cysteine residues in 
the epitope region by alanine  (3-181 C  "-," A in Fig.  9 B). 
These findings indicated that the structure to which the Abs 
bind is not the reduced form of the protein, but the cystine 
loop formed between the cysteine residues  at positions 163 
and  178. The fact  that  this protein can be recognized in 
Western blotting after its complete reduction and denatura- 
tion suggests that the primary structure of the protein in 
this region dictates correct refolding of the denatured receptor, 
as well as reformation of the cysteine link. 
The mapping of epitope E to the COOH-terminal end 
of the cysteine-rich module points to a correlation between 
the effects of the various  Abs against the extracellular  do- 
main ofp75-R on TNF function and the location of the epi- 
tope to which they bind (Table 1).  Abs that bind to the 
membrane-proximal part of the extracellular domain- to its 
COOH-terminal cysteine loop and the spacer region-have 
different effects on TNF function and binding from those 
of most of the Abs that bind to the membrane-distal part. 
Only the two Abs that bind to epitope D  showed a mixed 
type of effect, raising the possibility that this epitope is lo- 
cated at the boundary between the two regions. 
Discussion 
Involvement of p75-R in the cytocidal effect of TNF was 
explored in this study by probing the function of this receptor 
with Abs that bind to different regions in its extracellular 
domain. The results (summarized in Table 1) indicated that 
p75-R contributes to the cytocidal effect by at least two kinds 
of activities:  its own signaling activity and control of the 
access of TNF to p55-R. 
Examination of the effects of Abs on the viability of HeLa 
cells manipulated to express large amounts of  wild-type p75-R 
indicated that p75-R plays a role in signaling for the cyto- 
cidal effect of TNF. Anti-p75-R Abs were cytotoxic to these 
cells even in the absence of TNF or anti-p55-R Abs, and en- 
hanced the cytocidal effect of anti-p55-R Abs. These effects 
of the anti-p75-R Abs were correlated with their ability to 
cross-link  the receptor molecules, suggesting that the sig- 
naling occurs as a consequence of receptor aggregation. To 
some extent, these effects were also dependent on the site 
to which the Abs bind within the receptor.  Abs against epi- 
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Figure 8.  TNF enhances the binding of Abs to epitopes D or E and 
to the spacer region of p75-K: assessment by ceU-ELISA. Effects of TNF 
on the binding ofmAbs against epitopes A (number 13), D (number 67), 
and E (number 32), of Fab monovalent fragments of the Ab against epi- 
tope E, and of Abs against the spacer region. TNF (10,000 U/ml) was 
applied to HeLa p75WT cells for 10 min. The cells were then fixed with 
glutaraldehyde. Binding  of the Abs applied at the indicated concentrations, 
after washing of unbound  Abs with RIPA buffer, was assessed as described 
in Materials and Methods. Similar results were obtained when the binding 
of Ab number 32 or of its Fab fragments was quantified by applying radio- 
labeled preparations of these Abs to the cells. 
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topes A, B,  C,  and D, at the membrane-distal part of the 
receptor's extraceUular domain, had stronger effects than those 
that bind to epitope E or to the spacer region (Fig. 2). How- 
ever, the epitope E and anti-spacer Abs showed increased cy- 
totoxicity when their ability to cross-link the receptor mole- 
cules was enhanced by their cross-linking with anti-Ig Abs. 
The partial site dependence of their effects may reflect differ- 
ences in the ability of the Abs to impose an orientation on 
the receptor molecules resembling that attained when TNF 
binds to them. Abs that bind to epitopes A, B, C, and D 
may be better able to bring about this orientation, possibly 
because their binding sites to the receptor are close to the 
region at which TNF binds (as reflected in the ability of the 
Abs that bind to epitopes A, B, and C to interfere with TNF 
binding,  Fig.  6 A). 
Similar to the signaling activity of p75-R,  signaling for 
the cytocidal effect by p55-R is triggered upon receptor aggre- 
gation (33).  Yet, in spite of this similarity in mode of trig- 
gering of the receptors, and the apparent identity of their 
impact on the cell, it seems that the mechanisms of signaling 
for cell death by the two receptors differ, at least at their ini- 
tial step. This difference was evident from the way in which 
stimulation of each receptor affected the activity of the other. 
HeLa cells prestimulated with Abs against p55-R became al- 
most completely unresponsive to the cytocidal effect of these 
Abs (33, and the present study), yet showed a response greater 
than the additive effect of the two receptors when subsequently 
stimulated with Abs against p75-R.  It thus seems that the 
signals provided by p75-R are able to reverse the desensitiza- 
tion of p55-R or perhaps to uncover preformed p55-R-medi- 
ated signals in the desensitized cells and act in concert with 
them. The possible occurrence of receptor-specific desensiti- 
zation is consistent with a prior study which indicated that 
desensitization of cells to TNF cytotoxicity (51, 55, 56) in- 
volves, in addition to activities that antagonize the cytocidal 
effect itself (57-59),  activities that inhibit signaling-related 
mechanisms (60). 
Although capable of triggering a cytocidal effect in HeLa 
cells, the anti-p75-R Abs were unable to do so in A9 cells, 
irrespective of whether the transfected human p75-R that 
they expressed was of full-length or cytoplasmicaUy truncated. 
The nature of this difference between the A9 and the HeLa 
cells is not clear. It is unlikely to reflect a species specificity 
barrier, as human p75-R does have the ability to trigger TNF 
effects in mouse cells  (37).  Moreover, a recent study (38) 
demonstrated that Abs against endogenous mouse p75-R 
cannot trigger a cytocidal effect in cells of the mouse L929 
line, which are closely related to the A9 cells.  Perhaps the 
difference is related to the way in which TNF cytotoxicity 
is regulated in the two cell lines. In L929 and A9 cells, unlike 
in HeLa cells, preexposure to TNF or to Abs against p55-R 
does not result in desensitization (55, and data not shown). 
It thus appears that the desensitization mechanisms which 
restrict the signaling for cell death in HeLa cells, and which 
seem to be reversed upon triggering ofp75-R, do not operate 
in A9 cells. 
Effects of the anti p75-R Abs on TNF cytotoxicity were 
correlated only in part with their own ability to trigger cyto- Figure 9.  Mapping of epitope E. (A) Schematic representation of the 
bacterial constructs used for mapping. Recombinant peptides corresponding 
to parts of the extracellular domain of p75-R were expressed in Escherickia 
coil  Constructs differing in their COOH termini were obtained by use 
of the pET8c vector, whereas products  differing in their NH2-termini 
were obtained as fusion proteins with the maltose binding  protein (MBP 
constructs) by use of the pMalcRl vector. Recognition of these contructs 
by Abs against epitope E was assessed by Western blot analysis, as de- 
scribed in Materials and Methods and exemplified in B below. Constructs 
that reacted with the Abs are denoted in bold letters. The three mAbs 
against epitope E exhibited identical reaction patterns with the constructs. 
The sequence of amino acid residues in the extracellular domain of p75-R 
is shown in part.  Residues found to be within the region of epitope E 
are denoted in bold letters. The two cysteine residues in it are underlined. 
(TM) Transmembrane domain. (B) An example of the Western blot used 
to map epitope E. After IFIG induction, samples (0.1 ml) of bacterial 
cultures expressing the indicated products were lysed in SDS-PAGE  sample 
buffer and analyzed by SDS-PAGE (12% acrylamide). Western blotting 
was performed with mAb number 32 and goat anti-mouse Igs linked to 
horseradish peroxidase in the first and second steps of probing, respec- 
tively, as described in Materials and Methods. The urine-derived soluble 
form of p75-R (TBP, 0.36/~g [2]) served as a positive control.  (Arrow- 
cidal activity, alone or in the presence of anti-p55-R Abs (see 
Table 1). The partial nature of these correlations suggests that 
p75-R contributes to the cytocidal function of TNF not only 
by its signaling activity,  but also in another manner. The 
differences between the signaling effects of the Abs alone and 
their overall effects on TNF cytotoxicity were particularly 
notable in the transfected A9 cells and in HeLa cells expressing 
cytoplasmically truncated p75-R. Even though in these cells 
the Abs themselves did not  trigger  signaling,  they had a 
significant effect on the killing of the cells by TNF. This was 
true also when the Abs were applied as Fab monovalent frag- 
ments (Table 1), indicating that this Ab-induced modulation, 
unlike triggering of the signaling activity of p75-R, does not 
involve cross-linking of p75-R. Two ways of modulation, de- 
pending on the site of Ab binding to the receptor,  were ob- 
served. Abs that bind to the membrane-proximal part of the 
extracellular  domain of p75-R, i.e., to its COOH-terminal 
cysteine loop or to the spacer region, inhibited the cytocidal 
effect of TNF. This inhibition was observed in all transfec- 
tants studied, including the HeLa p75WT cells. Abs that 
bind to epitopes A, B, or C at the membrane-distal part of 
the extracellular  domain, and which in HeLa p75WT cells 
triggered signaling for cytotoxicity, enhanced the cytocidal 
effect also in cells that could not respond to signaling by p75-R 
(A9 cells and HeLa p75CT). In the latter cells, all the above 
Ab effects on TNF cytotoxicity were also observed when the 
Abs were applied as Fab monovalent fragments (Table 1). 
Several points of evidence indicate that these two ways of 
modulation reflect an ability of p75-R to control the access 
of TNF to p55-R.  (a) Because modulation was also obser- 
vated in cells in which p75-R could not signal for cytotox- 
icity,  it must reflect the effect(s) of p75-R (specifically, of 
its extracellular domain) on the cytotoxicity signaled by p55-R. 
(b) The modulation affected only the triggering, not the ac- 
tual mechanism of signaling. Cells whose killing was trig- 
gered by agonistic Abs against p55-R showed no protection 
from the killing when treated with Abs that bind to the 
membrane-proximal part of the extracellnlar domain of p75-R, 
nor enhancement of it when treated with Fab monovalent 
fragments of Abs that bind to the distal part of the extracel- 
lular domain. (c) Modulation of TNF function  by the different 
Abs was inversely related to their effect on TNF binding to 
p75-R. Potentiation of TNF activity was observed with those 
Abs that displace TNF from p75-R, and inhibition of TNF 
function was seen with Abs that enhance its binding. 
Two possible mechanisms by which the access of a ligand 
heads) Location of the recombinant peptides that did not react with the 
Ab. This location was defined both by Coomassie blue staining and by 
Western blot analysis of the proteins, using rabbit polyclonal Abs against 
the soluble form ofp75-R (2). (Left)  Molecular weight markers. (C) ELISA 
for the binding  of synthetic peptides by an Ab against epitope E. Compar- 
ison for binding  to Ab number 32 between peptides whose sequences cor- 
respond to residues 165-180 (O), 163-180 (,),  162-180 (D), or 160-180 
(0) in p75-R and a recombinant protein  that contains the sequence of 
epitope E (a fusion protein comprised of MBP linked to a recombinant 
protein corresponding to amino acids 125-192 in p75-R) was assessed as 
described in Materials and Methods.  Similar results were obtained with 
the two other Abs against epitope E. 
456  Role of p75 TNF Receptor  in TNF Cytotoxicity to its receptor can be controlled  by other, coexpressed, receptors 
were recently proposed. One was presented in a study that, 
like the present one, concerned the interactions of the two 
TNF-Rs (38),  and the other in a study of the interactions 
of the two receptors for IL-1 (61). The two proposed mecha- 
nisms have practically opposing consequences. According to 
the first, interactions between the two receptors can result 
in enhancement of signaling; it was suggested that the p75 
TNF-R is capable of"ligand passing", i.e., of presenting TNF 
to p55-R in such a way that its binding to p55-R is enhanced. 
The second mechanism can account for inhibitory interac- 
tions between two receptors. It was suggested that the type 
II IL-1 receptor serves as a "decoy receptor" which inhibits 
the binding of IL-1 to the type 1 IL-1 receptor by its own 
ability to bind IL-1. Whether and to what extent either of 
these two ways of modulation contributes to the observa- 
tions of the present study is not clear. Perhaps both are in- 
volved. 
The enhancement of TNF cytotoxicity by its displacement 
from p75-R with Abs against epitopes A, B, and C (in those 
transfectants  where p75-R cannot signal) indicates that this 
receptor can have an inhibitory effect on the function ofp55-R. 
A "ligand passing" mechanism cannot account for this effect 
since it should result not in inhibition but in enhancement 
of signaling.  The inhibitory effect can however be explained 
by assuming that p75-R functions as a decoy receptor.  At 
the levels attained in the transfected cells of this study, this 
receptor, by binding TNF, may have decreased the concen- 
tration of TNF in the cell culture and thus reduced the acti- 
vation of p55-R. 
On the other hand, the inhibition of TNF cytotoxicity 
by Abs that bind to the membrane-proximal part of the ex- 
tracellular domain ofp75-R is unlikely to be due to its func- 
tion as a decoy receptor.  Although these Abs decrease the 
dissociation of TNF from p75-R, this decrease is rather mild 
and results in only a small enhancement of TNF binding to 
the cells (Fig. 6 A), without any significant  decrease in the 
concentration of TNF in the cell growth media (our unpub- 
lished data).  Perhaps the Abs, by inhibiting dissociation of 
TNF from p75-R, slow down ligand passing between the 
two receptors (38). 
Even though the action of decoy receptors and the process 
of ligand passing result in opposing effects, they may well 
co-occur, since they relate to different ways ofligand binding. 
Decoy receptors affect the access ofligands in the cell's milieu. 
The way in which ligand passing occurs is not clear, but it 
seems plausible that it occurs by transient formation of a ter- 
nary complex of the ligand with the two receptors, without 
involvement of the ligand found in the fluid phase com- 
partment. 
The way in which binding of Abs  to  the membrane- 
proximal part ofp75-R, quite remote from the ligand-binding 
site, decreases the rate of TNF dissociation from the receptor 
remains to be clarified. The data presented in this paper indi- 
cate that these Abs and TNF have mutually positive effects 
in their binding to the receptor.  The amounts of the Abs 
that bound to the membrane-proximal part of the extracel- 
lular domain were the same in cells treated or untreated with 
TNF. However, the increased ability of the Abs to remain 
associated with the TNF-bound receptor in the presence of 
detergent indicates  an increased efficacy of Ab binding. A 
likely explanation for the mutual effects of the Abs and TNF 
in their interaction with the receptor is that the binding of 
Abs to the membrane-proximal part of the extracellular do- 
main and the binding of TNF to the distal part cause similar 
conformational changes in the receptor, and thus enhance each 
other allosterically. Induced conformational changes have also 
been observed in the extracellular  domains of a number of 
other receptors as a consequence of their binding to their 
respective agonists (62-64). Notably, both the structure of 
epitope E (cysteine loop) and its size (17 residues, significantly 
above the size characteristic of sequence epitopes) would allow 
it sensitively to reflect changes in receptor conformation. 
The findings of this study, although obtained only by ex- 
amining the cytoddal activity of TNF, have general implica- 
tions for our understanding of the function of the two TNF- 
Rs. The ability of p75-R to participate doubly in an effect 
signaled by p55-R-both by controlling the access of TNF 
to p55-R and by its own signaling activity-implies that, 
even if the two TNF-Rs can be triggered separately, they 
constitute part of one functional unit. The ways in which 
the expression and function ofp75-R are regulated are there- 
fore likely to affect not only those TNF activities  that are 
triggered by this particular receptor,  but also the intensity 
of the effects of TNF signaled by p55-R. Moreover,  phar- 
maceutical agents affecting p75-R may have a general impact 
on TNF function, including those activities whose major sig- 
naling'receptor is p55-R. Such pharmacological modulation 
is perhaps indicated by the mode of function of Abs that bind 
to the membrane-proximal part of the extracellular domain 
of p75-R, particularly those that bind to its COOH-terminal 
cysteine loop. Because they are able to inhibit the activation 
of p55-R by TNF, and are unable to trigger the signaling 
activity of p75-R (see Fig.  2), these Abs may be useful as 
inhibitors of TNF function. Particularly suitable targets for 
such inhibition are cells of the monocytic and lymphocytic 
lineages, where the predominant receptor is p75-R yet many 
of the TNF effects depend on the signaling activity of p55-R 
(65). Preliminary findings in our laboratory indicate that Abs 
against epitope E can inhibit the effects of TNF in such cells, 
just as in the transfected cells examined in the present study, 
even though TNF binding to them is enhanced. In view of 
the marked conservation of various structural features in the 
cysteine~rich  module that characterizes the NGF/TNF receptor 
family, particularly the location of the cysteine residues,  it 
seems plausible that these structural features have similar func- 
tions in the different members of this family. It would be 
of interest to determine whether the COOH-terminal cys- 
teine loops in the extracellular domains of the various other 
receptors of this family display features similar to those ob- 
served in p75-R and are affected in the same way by Ab 
binding. 
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